trial

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCTId NCT01774435
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 35 (actual)
Sponsored by Endo USA Inc., a Keenova Therapeutics Company
Primary completion 2013-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
35 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-10
Primary completion
2013-10
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
EN3342

Sponsors

Endo USA Inc., a Keenova Therapeutics CompanyLead Sponsor

Investigators

1
Robert Litman, MDPrincipal Investigator

Sites

1 total
Marlton, United States

Facts & assertions

4 sourced
Enrollment
35
Phase
PHASE1
Primary Completion Date
2013-10
Status
COMPLETED
relationships
The graph out of here
drug
EN3342
drug
lead_sponsor
Endo USA Inc., a Keenova Therapeutics Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Robert Litman, MD
person